Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved
Platforms that continue offering compounded semaglutide broadly face potential FDA enforcement action
If you accidentally shook the vial and it's now foamy, let it sit undisturbed in the fridge for 1530 minutes until the foam settles
Your PlexusDx report provides educational, personalized insights related to genetic predispositionssuch as genes tied to appetite regulation (FTO), insulin sensitivity (TCF7L2), and calcium/vitamin D transport (GC)to help explain why nutrient timing and nutrient density may matter for long-term success while using GLP-1 therapy
Sculpt MD MedSpa in Livermore is one of the premier medical spas in the Tri-Valley area